BridGene Biosciences, Inc. is a biotechnology company committed to develop covalent drugs for unmet medical needs in different disease areas. BridGene’s proprietary IMTACTM platform overcomes the bottleneck of conventional drug discovery, and pioneered new avenues to discover small molecules for high-value yet hard-to-drug targets , thereby greatly expanding the druggable space of small molecule drugs.
We are seeking talented and motivated individuals to join our team. This is a fantastic opportunity to learn and use cutting-edge science to tackle unmet medical needs. We will work together to build an exciting, science-driven biotechnology company.
Sunnyvale, CA, Dec 7, 2018 – BridGene Biosciences, Inc., a biotechnology company deploying a revolutionary chemoproteomic platform to discover novel targets and develop new therapeutics for unmet medical needs, today …
Sunnyvale, CA, October1,2018 – BridGene Biosciences, Inc., a biotechnology company, today announced that the National Institutes of Health hereby awarded the Company a phase I Small Business Innovation Research (SBIR) grant. The grant will be utilized for the development of IMTAC …
Sunnyvale, CA, May 18, 2018 – BridGene Biosciences, Inc., a biomedical company based on novel and high-throughput chemical proteomic platform, announced the formation of its Scientific Advisory Board (SAB) and …
